

AD_____

Award Number: W81XWH-13-1-0486

TITLE: Early Recognition of Chronic Traumatic Encephalopathy through FDDNP PET Imaging

PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation
Cleveland, Ohio 44195

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2013 - 29 Sep 2014	
4. TITLE AND SUBTITLE Early Recognition of Chronic Traumatic Encephalopathy through FDDNP PET Imaging				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0486	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Charles Bernick, MD,MPH Email: bernicc@ccf.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cleveland Clinic Foundation Cleveland, Ohio 44195				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The PET biomarker, F-FDDNP (2-(1-{6-[(2-[F-18]fluoroethyl(methyl)amino]-2-naphthyl) ethylidene) malononitrile) [FDDNP] has shown sensitivity for in vivo detection of tau in addition to I -sheet-containing brain amyloid neuroaggregates. Tau protein in a characteristic distribution is felt to be the cardinal pathologic feature of Chronic Traumatic Encephalopathy. This project will examine whether FDDNP PET imaging correlates with, and/or can predict, decline in cognitive function in those exposed to cumulative head trauma. All operational aspects of this study have been accomplished including local IRB approval, identification of potential subjects from the Profesional Fighters Brain Health Study to rec uit, logistics of the study visit and PET FDDNP imaging, case report forms, and electronic data entry. Actual enrollment of subjects has been delayed awaiting approval from tie Human Research Protection Office.					
15. SUBJECT TERMS- Traumatic Brain Injury, Positron Emission Tcmography					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 5	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Overall Project Summary.....	4
4. Key Research Accomplishments.....	4
5. Conclusion.....	5
6. Publications, Abstracts, and Presentations.....	5
7. Inventions, Patents and Licenses.....	5
8. Reportable Outcomes.....	5
9. Other Achievements.....	5
10. References.....	5
11. Appendices.....	5

Introduction: Blast injuries and other head injuries sustained in battle have been associated with the development of chronic traumatic encephalopathy (CTE). Pathological series have indicated that a characteristic feature of CTE is accumulation of tau protein in the brain. Until very recently, there has been no reliable way of measuring tau deposition in the brain during life. One PET biomarker, F-FDDNP (2-(1-{6-[(2-[F-18]fluoroethyl(methyl)amino]-2-naphthyl} ethylidene) malononitrile) [FDDNP] has shown sensitivity for in vivo detection of tau in addition to A β -sheet-containing brain amyloid neuroaggregates. This project will examine whether FDDNP PET imaging correlates with, and/or can predict, decline in cognitive function in those exposed to cumulative head trauma.

Keywords: Traumatic Brain Injury, Chronic Traumatic Encephalopathy, PET imaging, Tau

Overall Project Summary: Preparation for enrollment of participants was completed including: the development of a Standard Operating Procedure manual, creation of case report forms, determination of procedures for transfer of FDDNP ligand from production at UCLA to delivery at the Cleveland Clinic, generation of a list of subjects from the Professional Fighters Brain Health Study that would be eligible for enrollment, and local IRB approval (including research monitoring plan).

Though we had initially projected that the tasks listed above would be completed within the first 6 months of the project *start*, we faced significant delays due to two factors. One delay was due to the time required to finalize the contractual service agreement between UCLA and Cleveland Clinic. The current point of stall is at the Human Research Protection Office. Our project has been under review by HRPO for close to 6 months; we have provided response to all their queries and are awaiting approval.

Once we obtain approval from HRPO, we anticipate enrolling the initial subjects within 6 weeks. However, in order to complete the 3 year follow up of subjects, we will need to extend the completion date accordingly. Once we begin enrollment of subjects, we do not anticipate any further delays in the conduct of the study.

Key Research Accomplishments: Not Applicable

Conclusion: There remains a need for biomarkers that can identify individuals at risk of CTE. Molecular imaging agents such as FDDNP hold promise as a means of revealing tau pathology and potentially could be included in a diagnostic algorithm.

Publications, Abstracts, Presentations: As enrollment and data collection has not occurred, we have had no publications/abstracts/presentations

Inventions, Patents, Licenses: Not applicable

Reportable Outcomes: None

Other Achievements: None

References – None

Appendices – None